Prognostic significance of \textit{NOTCH1} and \textit{FBXW7} mutations in pediatric T-ALL

Yucel Erbilgin\textsuperscript{a}, Muge Sayitoglu\textsuperscript{a}, Ozden Hatirnaz\textsuperscript{a}, Omer Dogru\textsuperscript{b}, Arzu Akcay\textsuperscript{c,d}, Gulen Tuysuz\textsuperscript{c,d}, Tiraje Celkan\textsuperscript{b}, Gonul Aydogan\textsuperscript{c,d}, Zafer Salcioglu\textsuperscript{c,d}, Cetin Timur\textsuperscript{e}, Lebriz Yuksel-Soycan\textsuperscript{d}, Umit Ure\textsuperscript{f}, Sema Anak\textsuperscript{g}, Leyla Agaoglu\textsuperscript{g}, Omer Devecioglu\textsuperscript{g}, Inci Yildiz\textsuperscript{b} and Ugur Ozbek\textsuperscript{a,*}

\textsuperscript{a}Institute of Experimental Medicine, Department of Genetics, Istanbul University, Istanbul, Turkey
\textsuperscript{b}Pediatric Hematology Divisions of Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
\textsuperscript{c}Department of Pediatrics, Bakirkoy Maternity and Childrens Hospital, Istanbul, Turkey
\textsuperscript{d}Turkish BFM Study Group, Istanbul, Turkey
\textsuperscript{e}Unit of Pediatric Hematology, Ministry of Health Goztepe Teaching Hospital, Istanbul, Turkey
\textsuperscript{f}Department of Internal Medicine, Haseki Education and Research Hospital, Istanbul, Turkey
\textsuperscript{g}Pediatric Hematology Division of Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

Abstract. The NOTCH signaling pathway plays important role in the development of multicellular organisms, as it regulates cell proliferation, survival, and differentiation. In adults, it is essential for the T- or B-lymphocyte lineage commitment. \textit{NOTCH1} and \textit{FBXW7} mutations both lead the activation of the NOTCH1 pathway and are found in the majority of T-ALL patients. In this study, the mutation analysis of \textit{NOTCH1} and \textit{FBXW7} genes was performed in 87 pediatric T-ALLs who were treated on the ALL-BFM protocols. In 19 patients (22%), activating \textit{NOTCH1} mutations were observed either in the heterodimerization domain or in the PEST domain and 7 cases (10%) demonstrated \textit{FBXW7} mutations (2 cases had both \textit{NOTCH1} and \textit{FBXW7} mutations). We also analyzed the relationship of the mutation data between the clinical and biological data of the patients. \textit{NOTCH1} and \textit{FBXW7}, \textit{NOTCH1} alone were found correlated with lower initial leucocyte counts which was independent from the sex and T- cell immunophenotype. However, \textit{NOTCH1} and \textit{FBXW7} mutations were not predictive of outcome in the overall cohort of pediatric T-ALLs.

Keywords: T-ALL, NOTCH1, FBXW7, mutation, prognosis

1. Introduction

T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes, generally characterized by very high circulating blast cell counts, mediastinal masses and central nervous system involvement [1,2]. It affects both children and adults and is rapidly fatal [3]. Although the outcome of pediatric ALL patients has improved in recent decades due to intensified therapies, less success has been achieved in adult T-ALL [1,4–7]. Malign transformation of T-cell is caused by chromosomal translocation and other genetic, epigenetic abnormalities which lead to loss of cell-cycle control, unlimited self-renewal capacity, impaired differentiation and increased blastic cell proliferation [8].

Less than 1% of T-ALL shelter chromosomal translocation t(7;9) (q34;q34.3) involves \textit{NOTCH1} [9]. The \textit{NOTCH1} gene encodes regulatory single-pass transmembrane receptor that is evolutionarily conserved [10] and it is essential for T- or B- lymphocyte lineage commitment in hematopoietic progenitors [11]. Weng et al. demonstrated activating \textit{NOTCH1} muta-
tions in more than 50% of T-ALL [12]. This observation gives an idea that NOTCH has an important role in T-ALL pathogenesis. It is reported that NOTCH signaling is also activated in cancers of other tissues with epithelial origin like breast, salivary gland, and colon [13–16].

The extracellular part of NOTCH1 comprises 36 epidermal growth factor (EGF)-like repeats, three Lin12/Notch repeats (LNRs), one N-terminal heterodimerization domain (HD-N) and one C-terminal heterodimerization domain (HD-C). The intracellular subunit consists of a RAM domain, a strong transcriptional activation domain, seven iterated ankyrin-like repeats and a C-terminal PEST domain [17–19]. By binding of NOTCH ligands, NOTCH receptor experiences a series of tightly reduced proteolytic cleavages followed by the translocation of the intracellular domain of NOTCH1 (ICN) into the nucleus where NOTCH interacts with other factors and regulates the transcription of many genes [20–22].

**NOTCH1** mutations have been detected within HD-N, HD-C and PEST domains. These mutations cause up-regulation of NOTCH1-dependent signal transduction [12]. Mutations of HD-N and HD-C increase active ICN by destabilizing the intersubunit association [23, 24]. Mutations of the PEST domain enhance ICN turn over [25]. Loss-of-function mutations of **FBXW7** gene also lead to NOTCH1 activation by, inhibition of ubiquitin-mediated degradation of the activated form of **NOTCH1** [26, 27]. Several studies have reported mutations of **FBXW7** gene in various tumors including endometrial cancers, T-ALL and inactivation of **FBXW7** has been shown to lead to an increased genetic instability [28–30]. However, the clinical effect of **NOTCH1** mutation in T-ALL still remains controversial and **NOTCH1/FBXW7** mutations remain to be investigated. In this study, we analyzed the clinical and prognostic significance of **NOTCH1/FBXW7** mutational status in 87 pediatric T-ALL patients.

2. **Design and methods**

2.1. **Patients**

Bone marrow/peripheral blood samples were obtained from 87 pediatric patients with T-ALL, who were diagnosed between 1997 and 2008 in Department of Pediatrics, Bakirkoy Maternity and Childrens Hospital; Pediatric Hematology Division of Istanbul Medical Faculty, Istanbul University; Unit of Hematology, Sisli Etfal Education and Research Hospital; Unit of Pediatric Hematology, Ministry of Health Goztepe Teaching Hospital; Department of Internal Medicine, Haseki Education and Research Hospital, Istanbul, Turkey. At the time of diagnosis, bone marrow (n = 77) or peripheral blood samples (n = 10) from T-ALL patients (median age of 7, 6 years; min, 22 days- max, 16 years) were included in this study. Relapse material was available only from one of the patients and all samples were stored at −80°C after homogenization in RLT buffer (Qiagen, GmbH, Germany). Male, female ratio is 2.5:1. Immunophenotypic subgrouping of T-ALL is done according to the European Group for the Immunological Characterization of Leukemia (EGIL) guidelines [31]. All T-ALL patients received chemotherapy according to the ALL-Berlin-Frankfurt-Munster (BFM) 2000 protocol. The study was approved by the ethical committee of Istanbul Medical Faculty, Istanbul University and informed consents were obtained from all participating patients.

2.2. **RNA isolation and cDNA synthesis**

Total RNA was isolated by Qiagen RNeasy Protect kit (Qiagen, GmbH, Germany). RNA samples were treated by DNAse (1U/µg) for the possible DNA contaminations (MBI Fermentase, Germany). 1µg of total RNA was used for cDNA synthesis using random hexamers and MMLV reverse transcriptase according to the protocol provided by the manufacturer (MBI Fermentase, Germany) [32].

2.3. **Detection of NOTCH1 mutations**

N-terminal region of heterodimerization domain (HD-N) (exon 26), the C-terminal region of the heterodimerization domain (HD-C) (exon 27), the PEST domain (exon 34) of the **NOTCH1**, and exons 7,8,9,10 and 11 of WD40 domain of **FBXW7** were amplified by using standard protocol [33]. Because of low sensitivity (20%) of direct sequencing, we used denaturing high-performance liquid chromatography (dHPLC) (WAVE DNA Fragment Analysis System, Transgenomics) technique, which have a sensitivity of 1–5% in mutation detection, to increase the sensitivity in addition to the sequencing [34–36]. All sequencing chromatograms analyzed by CLC combined Workbench software (V3.6.1, Denmark).
2.4. Statistical analyses

Proportional differences between groups were analyzed by X² test or Fisher’s exact tests. The median follow up was 11.8 months (min 1 - max 133 months). Overall survival was defined by the interval from the date of diagnosis to the date of death or last follow up. Relapse-free survival was the duration from the date of complete remission to the date of analysis or to the first event (failure to achieve remission (early death or resistant leukemia), relapse or death in complete remission). The Kaplan-Meier method was used to estimate survival rates. We compare the differences with the 2-sided log-rank test. Multivariate survival analysis was estimated according to the Cox regression model. All statistical analyses were done by SPSS 16.0 software and GraphPad Prism software.

3. Results

A total of 87 T-ALL patients were analyzed for NOTCH1 gene mutations. Heterozygous NOTCH1 mutations were found in 19 (22%) of 87 T-ALL samples. We have observed mutations in HD domain in 11 patients (12%), in the PEST domain in 6 patients (7%) and in both domains in 2 patients (3%). All the detected NOTCH1 mutations were listed in Table 1. Nine of the identified mutations were new mutations, whereas the remaining mutations had been reported previously [12, 37].

Table 1

| Patient no. | NucleotideΦ | Amino acid | Nucleotide | Amino acid |
|-------------|-------------|------------|------------|------------|
| Y2          | -           | 5062_5083 insT, 5093_5094 insT | - | 1694Q->1796*stop |
| T4          | 1436 G>A    | R479Q     | -          | -          |
| T7          | 1393 C>T    | R465C     | -          | -          |
| T12         | 4796 G>C    | R1599P    | 5062_5083 insT, 5093_5094 insT | 1694Q->1796*stop |
| T22         | 4757 T>C    | L1599P    | -          | -          |
| T41         | 5064 G>T, 5072 C>T, 5082 ins 5083 | 1694Q->1720*stop |
| T53         | -           | -          | -          | -          |
| T62         | -           | -          | 4681 G>A   | D1561N     |
| T70         | 1496G>A     | G498A     | 4724 T>C   | L1575P     |
| T73         | -           | -          | 7321_7322 ins TCCGCTCTGA, 7329 | K1608N, 2440S->2446*stop |
| T74         | -           | -          | 7553 C>T   | P2518L     |
| T77         | -           | -          | 4796 G>C   | R1599P     |
| T81         | -           | -          | 7331_7332 ins GAGCTCTGA, 7357 G>C | 2444V->2561*stop |
| T84         | -           | -          | 7180 C>T   | Q2394 *stop |
| T85         | 1948 dup gactgataaagcgg | 650 dup DLKT | -       |
| T87         | 1403 G>A    | R465H     | -          | -          |
| T89         | -           | -          | 7378 C>T   | Q2460 *stop |
| T92         | -           | -          | 4724T>C, 7195 C>T | L1575P, Q2399 *stop |
| T95         | -           | -          | 7356, 7378 insA, 7336_7337 insATG, 7338_7339 insGCC, 7354 CC>TG | 2445Q->2479*stop |
| T97         | -           | -          | 7207 C>T   | Q2403*stop |
| T110        | -           | -          | 5094 C>T   | D1698D     |
| T116        | 1228A>C     | T410P     | -          | -          |

Abbreviations: ins, insertion; dup, duplication. Φ Nucleotid number is according to the GenBank accession number NM_033632. Nucleotid number is according to the GenBank accession number NM_017617. Novel FBXW7 mutations are indicated by “♦” next to the sample identification number. Novel NOTCH1 mutations are indicated by “✸” next to the sample identification number. Nonsense mutations are indicated by an asterisk behind the amino acid number.
so had point mutations. All variations created premature termination codons in exon 28/29. (Figs S1 and S2). Furthermore, a single nucleotide polymorphism C5097T was observed in the HD-C domain in 20 (23%) of 87 T-ALL patients [12].

The PEST mutations were observed in eight patients and clustered in amino acid residues 2375 to 2571. Two of the PEST domain mutations have been reported before [12]; on the other hand, seven of them were new mutations. Seven of nine PEST domain mutations induced premature stop codons. All of these premature terminal codons were not expected to activate nonsense-mediated decay. Therefore, it is likely that these mutated mRNAs result in the production of C-terminally truncated proteins [38].

FBXW7 mutations were found in 7 (10%) of the 72 analyzed T-ALL samples (see Table 1). Two of the PEST domain mutations had co-existing NOTCH1 mutations, two in the HD domain (Tables 1 and 2).

The clinical and biological characteristics of the patients in this study are shown in Table 3. NOTCH1 and FBXW7 mutations had co-existing NOTCH1 mutations, two in the HD domain (Tables 1 and 2). The clinical and biological characteristics of the patients in this study are shown in Table 3. NOTCH1 and FBXW7 mutations had co-existing NOTCH1 mutations, two in the HD domain (Tables 1 and 2). The clinical and biological characteristics of the patients in this study are shown in Table 3. NOTCH1 and FBXW7 mutations had co-existing NOTCH1 mutations, two in the HD domain (Tables 1 and 2).
Fig. 1. Outcome of pediatric patients with T-ALL treated on BFM protocol. (A) Event-free survival by NOTCH1 mutation. (B) Overall survival by NOTCH1 mutation. (C) Event-free survival by FBXW7 mutation. (D) Overall survival by FBXW7 mutation. (E) Event-free survival by FBXW7 and/or NOTCH1 mutation. (F) Overall survival by FBXW7 and/or NOTCH1 mutation. $P$ value of 0.05 or less (two sided) was considered to indicate a statistically significant difference. None of the Kaplan-Meier analyses showed significant differences.

4. Discussion

In this study, we found 10% FBXW7 mutations and 22.2% NOTCH1 mutations in T-ALL patients. Mutations in NOTCH1 receptors domains are characterized with the up-regulation of NOTCH1-dependent signal transduction. HD domain mutations cause subunit dissociation or induce NOTCH1 to become susceptible to ligand-independent cleavage, resulting in increased ICN1 liberation and translocation to the nucleus [23,24,39]. Three of the patients showed L1575P mutations. This mutation, reduces the efficiency of furin cleavage and induce $\gamma$-secretase dependent NOTCH1 signaling and shows sensitivity to GSIs ($\gamma$-secretase inhibitors) (Table 1) [12,37]. The PEST domain is located in the C-terminal part of NOTCH1, which regulates protein turnover. Some deletions in this region increase the stability of the protein and up-regulation of NOTCH1 signaling [40–42]. Here, we define novel mutations as well as previously reported ones inside the PEST domain (Table 1) [12,38,43]. The novel mutations reside in the regions that control the protein stability, which
made us think that these mutations might cause the gain of function. The novel HD domain mutations are predicted to cause a substantial change of secondary structure by involving non-conservative amino acid substitution. Although this region is known to harbor most of the mutations, it can not be excluded that some of the newly identified mutations may represent polymorphism. The effect of novel mutations on ICN1 activity needs to be evaluated by functional analysis.

Mutations in the conserved protein-protein interaction domains of FBXW7 (R465C and R479Q) abrogate NOTCH1 binding and lead the NOTCH1 activation [33,44]. FBXW7 mutations have been associated with the HD domain which cause signal amplification, whereas FBXW7 mutations in PEST domain are less frequent [33,44,45]. Similar to other pediatric studies, we found no co-existing mutations in the PEST domain and the FBXW7 gene (Table 2). It has been proposed that mutations in the PEST domain relieve mutational pressure on FBXW7. Disruption of FBXW7 function may active in sustaining NOTCH signaling and also may prolong the half-life of substrates such as MYC [27, 33, 34]. Four novel mutations were found in FBXW7 and all of them were positioned in the evolutionary conserved side of the gene. Together the location and conservation statues suggest that the novel missense mutations may affect FBXW7 substrate targeting.

Currently, there are no genetic markers that reliably predict the treatment response or outcome for T-ALL [3,38]. Some genes (HOX11, TAL1, LYL etc.) have been reported to indicate a favorable or an unfavorable prognosis in a small number of patients and mRNA profiles might be used as a prognostic marker in the future [46–49]. The correlation between the NOTCH1 mutations and the clinical features and differences in disease outcome in T-ALL remains controversial [38,50]. Breit et al. [38] and Park et al. [51] revealed that NOTCH1 mutations are good prognostic markers for disease outcome where as Zhu et al. [52] showed that the NOTCH1 mutations are correlated with decreased survival time. Furthermore van Grotel et al. [53], in spite of a high mutation rate (57%), did not show any correlation with outcome. In this study, we couldn’t find any significant correlation between the presence of activating NOTCH1 and/or FBXW7 mutations and long-term treatment outcome, perhaps because the short term follow up of the patients. It is compatible with study of Grotel et al. but much larger studies of pediatric patients and longer follow up time will be demonstrated the impact of NOTCH1/FBXW7 on survival and treatment outcome more clearly [53].

Overall, 22.2% of our T-ALL patients had NOTCH1 mutations and 10% had FBXW7 mutations. While FBXW7 mutation frequency is similar to previous studies, prevalence of NOTCH1 mutation was relatively lower in our group [12,43,44,54]. Although the European groups revealed a mutation rate of more than 50%, the frequency of Japanese population was determined as 30.8% [51,52]. Variable frequency of NOTCH1 mutations reported in other studies may be due to several factors like ethnicity, combination of susceptibility variants, and number of patients.

The characterization of the NOTCH1 mutations and certain targets on the NOTCH pathway are important for developing novel and specific therapeutic strategies. Inhibitors of γ-secretase have recently been tested in T-ALL cell lines and were shown to induce cell cycle arrest [55]. Importantly, FBXW7 mutations have been associated with resistance to γ-secretase inhibitor treatment. On the other hand, some HD domain mutations such as L1575P show sensitivity to the treatment [33]. Therefore, the identification of NOTCH1 and FBXW7 mutations needs to be taken into account when choosing target therapies in T-ALL patients. In our knowledge, this is the first NOTCH1/FBXW7 mutations study in Turkish pediatric T-ALL patients. It is known that NOTCH signaling members have important roles in the thymus and deregulated NOTCH activation is an independent oncogenic event involved in human T-ALL oncogenesis.

Acknowledgements

This work was funded by the Research Fund of the Istanbul University (Project no: 819) and T.R. Prime Ministry State Planning Organization (Project no: 2005K120430). We thank Omer Uysal for contributing to statistical analysis.

Supplementary material

Supplementary data can be found on: http://www.istanbul.edu.tr/duyurular/2010/DMA0827.supporting.online.material.htm.

References

[1] L. Annino, M.L. Vegna et al., Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study, Blood 99 (2002), 863–871.
[2] A.A. Ferrando, D.S. Neuberg et al., Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia, *Cancer Cell* 1 (2002), 75–87.

[3] C. Grabher, H. von Boehmer et al., Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukemia, *Nat Rev Cancer* 6 (2006), 347–359.

[4] C.H. Pui, M.V. Relling et al., Acute lymphoblastic leukemia, *N Engl J Med* 350 (2004), 1535–1548.

[5] X. Thomas, J.M. Boiron et al., Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial, *J Clin Oncol* 22 (2004), 4075–4086.

[6] C. Linker, L. Dannon et al., Intensified and shortened cyclophosphamide chemotherapy for adult acute lymphoblastic leukemia, *J Clin Oncol* 20 (2002), 2464–2471.

[7] M. Hunault, J.L. Harousseau et al., Better outcome of adult acute lymphoblastic leukemia after early genoidentical allo geneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial, *Blood* 104 (2004), 3028–3037.

[8] S.A. Armstrong and A.T. Look, Molecular genetics of acute lymphoblastic leukemia, *J Clin Oncol* 23 (2005), 6606–6615.

[9] J. Aker, W. Peer et al., Functional analysis of the TAN-1 gene, a human homolog of Drosophila notch, *Cold Spring Harb Symp Quant Biol* 59 (1994), 125–136.

[10] S. Artavanis-Tsakonas, M.D. Rand et al., Notch signaling: cell fate control and signal integration in development, *Science* 284 (1999), 770–776.

[11] A. Wilson, H.R. MacDonald et al., Notch 1-deficient common lymphoid precursors adopt a B cell fate in the thymus, *J Exp Med* 194 (2001), 1003–1012.

[12] J. Artavanis-Tsakonas, M.D. Rand et al., Notch signaling: cell fate control and signal integration in development, *Science* 284 (1999), 770–776.

[13] C.H. Pui, M.V. Relling et al., Acute lymphoblastic leukemia, *Cancer Cell* 1 (2002), 75–87.

[14] C. Grabher, H. von Boehmer et al., Notch 1 activation in the molecular pathogenesis of T-cell acute lymphoblastic leukemia, *Nat Rev Cancer* 6 (2006), 347–359.

[15] C.H. Pui, M.V. Relling et al., Acute lymphoblastic leukemia, *N Engl J Med* 350 (2004), 1535–1548.

[16] X. Thomas, J.M. Boiron et al., Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial, *J Clin Oncol* 22 (2004), 4075–4086.

[17] M. Kraman and B. McCright, Functional conservation of notch1 and notch2 intracellular domains, *J Biol Chem* 276 (2001), 35847–35853.

[18] C.D. Hoemann, N. Beaulieu et al., Two distinct Notch1 mutant alleles are involved in the induction of T-cell leukemia by notch1, *Mol Cell Biol* 20 (2000), 7505–7515.

[19] J.C. Aster, L. Xu et al., Essential roles for ankyrin repeat and negative regulatory sequence that influences the leukemogenic activity of NOTCH1, *Mol Cell Biol* 26 (2006), 4642–4651.

[20] S. Jarriault, C. Brou et al., Signalling downstream of activated mammalian Notch, *Nature* 377 (1995), 355–358.

[21] C. Sanchez- Izirazry, A.C. Carpenter et al., Notch subunit heterodimerization and prevention of ligand-independent proteolytic activation depend, respectively, on a novel domain and the LNR repeats, *Mol Cell Biol* 24 (2004), 9265–9273.

[22] M.J. Malecki, C. Sanchez-Izirazry et al., Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes, *Mol Cell Biol* 26 (2006), 4642–4651.

[23] C.J. Fryer, J.B. White et al., Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover, *Mol Cell* 16 (2004), 509–520.

[24] M.J. Malecki, C. Sanchez-Izirazry et al., Leukemia-associated mutations within the NOTCH1 heterodimerization domain fall into at least two distinct mechanistic classes, *Mol Cell Biol* 26 (2006), 4642–4651.
PBX1 transgenic mice. Blood 96 (2000), 1906–1913.

[42] N. Gupta-Rossi, O. Le Bail et al., Functional interaction between SEL-10, an F-box protein, and the nuclear form of activated Notch1 receptor, J Biol Chem 276 (2001), 34371–34378.

[43] S.Y. Lee, K. Kumano et al., Mutations of the Notch1 gene in T-cell acute lymphoblastic leukemia: analysis in adults and children, Leukemia 19 (2005), 1841–1843.

[44] B.J. Thompson, S. Buonomano et al., The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia, J Exp Med 204 (2007), 1825–1835.

[45] R.S. Maser, B. Choudhury et al., Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers, Nature 447 (2007), 966–971.

[46] F. Speleman, B. Cauwelier et al., A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias, Leukemia 19 (2005), 358–366.

[47] V.E. Valge-Archer, H. Osada et al., The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells, Proc Natl Acad Sci U S A 91 (1994), 8617–8621.

[48] A.T. Look, Oncogenic transcription factors in the human acute leukemias, Science 278 (1997), 1059–1064.

[49] T. Taghon, K. Thys et al., Homeobox gene expression profile in human hematopoietic multipotent stem cells and T-cell progenitors: implications for human T-cell development, Leukemia 17 (2003), 1157–1163.

[50] V. Asnafi, A. Buzyn et al., NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL); a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study, Blood 113 (2009), 3918–3924.

[51] M.J. Park, T. Taki et al., FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma, Br J Haematol 145 (2009), 198–206.

[52] Y.M. Zhu, W.L. Zhao et al., NOTCH1 mutations in T-cell acute lymphoblastic leukemia: prognostic significance and implication in multifactorial leukemogenesis, Clin Cancer Res 12 (2006), 3043–3049.

[53] M. van Grotel, J.P. Meijerink et al., Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences, Leukemia 22 (2008), 124–131.

[54] M.R. Mansour, V. Duke et al., Notch-1 mutations are secondary events in some patients with T-cell acute lymphoblastic leukemia, Clin Cancer Res 13 (2007), 6964–6969.

[55] M. Shih le and T.L. Wang, Notch signaling, gamma-secretase inhibitors, and cancer therapy, Cancer Res 67 (2007), 1879–1882.